

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Tong Ren Tang Technologies Co. Ltd.**  
**北京同仁堂科技發展股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 1666)

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by the board of directors (the “**Board**”) of Tong Ren Tang Technologies Co. Ltd. (the “**Company**”) on a voluntary basis.

To the best knowledge of the directors, the workshops and production lines of pharmaceutical factory of the Company have complied with the requirements of the Good Manufacturing Practice (“**GMP**”) upon on-site inspection and technical audit and received the GMP Certificate issued by Beijing Food and Drug Administration. The related information is hereby announced as follows:

**I. Information related to GMP certificate**

Certificate Number: BJ20170283

Name of Enterprise: Pharmaceutical Factory of Tong Ren Tang Technologies Co. Ltd.

Address: Three groups of Changhe Village, Xinglong Town, Longquanyi District, Chengdu, Sichuan Province (Shared workshop within the group). West Xiaogudian Village, Qingyundian Town, Daxing District, Beijing. South of Fatou Village, Zhangjiawan Town, Tongzhou District, Beijing. Six Buildings of No. 201 of East Dongyonghetun Village, Tongzhou District, Beijing (Shared workshop within the group). No. 16 Tongji Beilu, Beijing Economic and Technology Development Zone, Beijing.

Scope of Authentication: Preprocessing and extraction of traditional Chinese medicine, preprocessing of traditional Chinese medicine, extraction of traditional Chinese medicine, extraction of traditional Chinese medicine, tablet, powder and hard capsule.

Date of Issue: 2017/09/06

Expiry Date: 2022/09/05

## II. The status of production line related to GMP certificate

No.	Name of production line	Designed production capacity	Key product(s)
1	Production line for extraction of traditional Chinese medicines	Chengdu: 1 million kg Tongzhou Zhangjiawan: 4 million kg Tongzhou Dongyonghetun: 1 million kg	As the production line is for the preprocessing process of the production, there is no key product.
2	Production line for preprocessing traditional Chinese medicines	Processing quantity of net material: 15 million kg Crushing quantity of raw material: 10 million kg	As the production line is for the preprocessing process of the production, there is no key product.
3	Production line of tablets and capsules workshops (including powder)	Tablets: 3,000,000,000 tablets Capsules: 50,000,000 capsules	Jingzhi Niu Huang Jiedu Tablets (京製牛黃解毒片), Tongbianling Capsules (通便靈膠囊), etc.

## III. Market condition

No.	Product Name	Dosage Form	Functions and Indication	Major Production Enterprises	Information of Similar Products in the Market
1	Jingzhi Niu Huang Jiedu Tablets (京製牛黃解毒片)	Tablets	Dissipating heat and detoxicating, dispelling wind and relieving pain. Treatment of symptoms arising from accumulated heat in the lung and stomach: dizziness, ulcers in the oral cavity and nose, toothache arising from the wind and fire, sore throat, sonitus and sore pain, constipation, itchiness of skin.	Pharmaceutical factory of the Company.	A total of 1 enterprise (being the Company) was granted the approval number for such product. The revenue of the Company generated from the sale of such product (in the specification of film-coated tablets) was about RMB7,410,000 in 2016.
2	Tongbianling Capsules (通便靈膠囊)	Capsules	Purging heat and removing stagnation, lubricating the intestines and relaxing the bowels. Treatment of heat-constipation, long time bedridden constipation, temporary abdominal distension and constipation, habitual constipation of the elderly.	Pharmaceutical factory of the Company, Shanxi Panlong Pharmaceutical Group Limited by Share Ltd (陝西盤龍藥業集團股份有限公司) and Xi'an Fangxing Pharmaceutical Co., Ltd. (西安方興製藥有限公司) and others.	A total of 88 enterprises were granted the approval number for such product. The sales revenue of the product of the Company was about RMB2,650,000 in 2016.

Note:

1. The above information is sourced from the official website of China Food and Drug Administration, etc.;
2. The Company could not obtain the specific sales information on the same type of products in the market through public information;
3. The above statistical results may be not comprehensive enough, and are for the purpose of reference only.

#### **IV. Impact on the Listed Company**

This is a re-authentication after the expiration of the original GMP Certificate. The aforesaid workshops passed the GMP authentication and were granted GMP Certificate, which indicates that the related production lines of the Company meet the requirements of new version of GMP. Obtaining the GMP Certificate for this time will be beneficial to maintain the stable production capacity of the Company and meet the market demands, and meanwhile it will not have any significant impact on the production and operation of the Company.

By order of the Board  
**Tong Ren Tang Technologies Co. Ltd.**  
**Gao Zhen Kun**  
*Chairman of the Board*

Beijing, the PRC  
18 September 2017

*As at the date of this announcement, the Board comprises Mr. Gao Zhen Kun, Mr. Gu Hai Ou, Mr. Rao Zu Hai, Mr. Li Bin, Mr. Wang Yu Wei and Ms. Fang Jia Zhi as executive Directors; Miss Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.*